Arcus Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
Arcus Biosciences, Inc. (RCUS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 300.85 thousand shares for the 3-month period ending 2019-09-30, per its 10-Q filed 2019-11-05.
Discontinued › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2019-11-05
- Arcus Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2019-09-30 was 300.85K shares, a 131.42% increase year-over-year.
- Arcus Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2019-06-30 was 1.31M shares, a 522.25% increase year-over-year.
- Arcus Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2019-03-31 was 1.78M shares, a 49.72% increase year-over-year.
- Arcus Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2018-09-30 was 130.00K shares, a 12.14% decline year-over-year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month |
|---|---|---|---|
| 2019-09-30 | 300.85K shares 10-Q · filed 2019-11-05 | 1.61M shares derived: sum of 2 quarters · filed 2019-11-05 | 3.39M shares 10-Q · filed 2019-11-05 |
| 2019-06-30 | 1.31M shares 10-Q · filed 2019-08-06 | 3.09M shares 10-Q · filed 2019-08-06 | |
| 2019-03-31 | 1.78M shares 10-Q · filed 2019-05-02 | ||
| 2018-09-30 | 130.00K shares 10-Q · filed 2019-11-05 | 340.81K shares derived: sum of 2 quarters · filed 2019-11-05 | 1.53M shares 10-Q · filed 2019-11-05 |
| 2018-06-30 | 210.81K shares 10-Q · filed 2019-08-06 | 1.40M shares 10-Q · filed 2019-08-06 | |
| 2018-03-31 | 1.19M shares 10-Q · filed 2019-05-02 | ||
| 2017-09-30 | 147.96K shares 10-Q · filed 2018-11-08 | 338.10K shares derived: sum of 2 quarters · filed 2018-11-08 | 1.01M shares 10-Q · filed 2018-11-08 |
| 2017-06-30 | 190.15K shares 10-Q · filed 2018-08-06 | 866.58K shares 10-Q · filed 2018-08-06 | |
| 2017-03-31 | 676.44K shares 10-Q · filed 2018-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |